Press Releases for ANSV

Press Releases
Anesiva, Inc. And Arcion Therapeutics Announce Merger Agreement ; - Creates New Company Focused on Targeted Pain Therapeutics That Address Large Markets With Unmet Needs -; - Conference Call Scheduled for Wednesday, August 5, 2009 at 8:30 AM EDT -
Anesiva, Inc. and Arcion Therapeutics Announce Merger Agreement
Anesiva Announces Going Concern Opinion and Nasdaq Notice - Apr 1 2009 11:10PM
Anesiva Announces Going Concern Opinion and Nasdaq Notice - Apr 1 2009 8:52PM
Anesiva Announces Planned Rights Offering
Biotechnology Value Fund Urges Stockholders to Remove and Replace Current Board of Avigen, Inc. In an Effort to Protect and Maximize Stockholder Value
Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
Anesiva Announces Changes to Its Board of Directors and Receives Notification From Nasdaq
BenchmarkJournal.Com (Complimentary) Analyst Review for DTV, ANSV, STEC and FFIV
Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
Anesiva Secures Financing for Up to $30 Million
Child Life Council Urges Parents to Think Ahead to Ease Child's Hospital Visit
Anesiva to Present at UBS Global Life Sciences Conference on September 24, 2008
Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
Anesiva Announces Appointment of William Houghton, M.D. as Senior Vice President and Chief Medical Officer
Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate Strategy and Milestones
Anesiva to Present at BioCentury Newsmakers Conference on September 4, 2008
Anesiva Announces Second Quarter 2008 Financial Results and Update
Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
Anesiva Announces June 11, 2008 Presentation at Needham 7th Annual Biotechnology & Medical Technology Conference
Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults - May 27 2008 12:59AM
Anesiva Announces May 22, 2008 Presentation at Citi Investment Research Global HealthCare Conference - May 27 2008 12:55AM
Anesiva Announces First Quarter 2008 Financial Results - Jun 1 2008 6:48AM
New Survey Finds Enhanced Pain Management for Blood Draw and IV Insertions in Children Would Benefit Patients, Families and Nursing Staff - Jun 1 2008 6:48AM
Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics - Jun 1 2008 6:48AM
Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast - Jun 1 2008 6:48AM
Anesiva Announces Expansion of Zingo Agreement in Europe - Jun 1 2008 6:48AM
Anesiva Announces New Zingo Marketing and Distribution Agreement
Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement